(WATCH) FDA Official Dr. Peter Marks Says Vaccinated Kids Have 5 FOLD Increase of Myocarditis

The U.S. Food and Drug Administration (FDA) needs to be splintered into a million pieces and scattered into the wind.

Add the U.S. Centers for Disease Control and Prevention (CDC) to the same category.

The corrupt three-letter public health agencies operate as financial arms of Big Pharma and bow to their demands.

Despite no health benefits whatsoever, the FDA authorized the Moderna and Pfizer/BioNTech COVID-19 shots for children five years and under.

One State Has Yet to Order COVID-19 Shots For Children Under 5

The FDA knows these toxic injections will harm babies and toddlers.

And they still authorized the experimental shots for the young age cohort.

They're complicit with 'Crimes Against Humanity' and 'Crimes Against Children.'

Dr. Peter Marks, the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration, discussed the incidence of myocarditis in the 12-17 year age range.

"This is a known phenomena in the 12-17-year-old age range, and the rate that it was seen in the 12-17-year-olds who were vaccinated seem to be about 5 fold higher than the baseline rate that we would expect," Dr. Marks said.

WATCH:

FDA official Dr. Peter Marks says vaccinated kids have a 5 fold increase of myocarditis. Why on earth are they pushing the COVID vaccine on babies? We still don’t know the long-term safety profile of these vaccines. pic.twitter.com/Ya3jdR3zRl

— Senator Ron Johnson (@SenRonJohnson) June 16, 2022

Yet, the FDA still authorized these dangerous injections for babies and toddlers.

Dr. Marks's FDA profile highlights the revolving door of corruption between the federal agency and the pharmaceutical industry.

He then moved on to work for several years in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University where he led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016.  Dr. Marks is board certified in internal medicine, hematology and medical oncology, and is a Fellow of the American College of Physicians.